Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intervention to Increase Screening for Glucocorticoid Induced Diabetes (CDA-GID)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Liron Caplan MD, PhD, VA Eastern Colorado Health Care System
ClinicalTrials.gov Identifier:
NCT01743963
First received: November 20, 2012
Last updated: June 5, 2015
Last verified: June 2015
Results First Received: March 27, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Prevention
Condition: Diabetes Mellitus
Interventions: Behavioral: Decision support
Behavioral: Usual Care

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Decision Support Intervention

Clinical pharmacists mediated computerized decision support

Decision support: Clinical pharmacists mediated computerized decision support

Usual Care

Clinicians' typical approach for GID monitoring

Usual Care: clinicians typical apporach for GID monitering


Participant Flow:   Overall Study
    Decision Support Intervention     Usual Care  
STARTED     21     17  
COMPLETED     21     17  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Decision Support Intervention

Clinical pharmacists mediated computerized decision support

Decision support: Clinical pharmacists mediated computerized decision support

Usual Care

Clinicians' typical approach for GID monitoring

Usual Care: clinicians typical apporach for GID monitering

Total Total of all reporting groups

Baseline Measures
    Decision Support Intervention     Usual Care     Total  
Number of Participants  
[units: participants]
  21     17     38  
Age, Customized [1]
[units: participants]
     
18 to 90 years     21     17     38  
Gender [2]
[units: participants]
     
Female     NA [2]   NA [2]   NA [3]
Male     NA [2]   NA [2]   NA [3]
Region of Enrollment  
[units: participants]
     
United States     21     17     38  
[1] We were not authorized by the IRB to record this information; however, all participants were between the ages of 18 and 90, as specified in the inclusion criteria.
[2] We were not authorized by IRB to record this information.
[3] Total not calculated because data are not available (NA) in one or more arms.



  Outcome Measures

1.  Primary:   Delay Interval (Days From Randomization Until the Provider Signs the Order for a hgbA1C Level).   [ Time Frame: 6 MONTHS ]

2.  Secondary:   Feasibility/Reach/Adoption   [ Time Frame: 12 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

3.  Secondary:   Feasibility/Reach/Adoption   [ Time Frame: 12 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   Feasibility/Reach/Adoption   [ Time Frame: 12 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No

5.  Secondary:   Feasibility/Reach/Adoption   [ Time Frame: 12 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Liron Caplan, Primary Investigator
Organization: Eastern Colorado Health Care System, VA
phone: 7208575103
e-mail: liron.caplan@ucdenver.edu



Responsible Party: Liron Caplan MD, PhD, VA Eastern Colorado Health Care System
ClinicalTrials.gov Identifier: NCT01743963     History of Changes
Other Study ID Numbers: 176843
Study First Received: November 20, 2012
Results First Received: March 27, 2015
Last Updated: June 5, 2015
Health Authority: United States: Federal Government